Island Pharmaceuticals Ltd · ASX:ILA
Island Pharmaceuticals — BioShares 2026
21 slides from Island Pharmaceuticals's conference presentation, Aug 7, 2026
Slide 1: Combatting Urgent Viral Disease Threats
COMBATTING URGENT VIRAL DISEASE THREATS Dual Approach to Advance Galidesivir as a Pan-Filovirus Medical Countermeasure BioShares 2026 Dr David Foster, CEO & Managing Director August 7, 2026 ASX: ILA
Slide 2: Cumulative Ebola cases in past outbreaks
Cumulative Ebola cases in past outbreaks Cumulative confirmed cases 2013-2016 West Africa - Ebola Zaire 2018-2020 DRC (Kivu) - Ebola Zaire 2018-2020 final total (3,375 cases) West Africa (Zaire) continues far above this axis (=28,600 total) Days since outbreak started Island Pharmaceuticals Limited
Slide 3: Cumulative Ebola cases in current vs past outbreaks
Cumulative Ebola cases in current vs past outbreaks 2026 BDBV outbreak has surpassed the 2018-2020 Ebola Zaire total in ~ 70 days Cumulative confirmed cases 2026 DRC - Bundibugyo (BDBV), this outbreak 2013-2016 West Africa - Ebola Zaire 2018-2020 DRC (Kivu) - Ebola Zaire 2018-2020 final total (3,375
Slide 4: Island Pharmaceuticals (ASX: ILA)
ISLAND PHARMACEUTICALS (ASX: ILA) TWO PROGRAMS TARGETING INFECTIOUS DISEASES Two, well advanced clinical stage programs Phase 2a/b PROTECT clinical trial in dengue with broad acting antivirals complete for ISLA-101 Major market potential via both programs, including Positive FDA feedback on Animal R
Slide 5: Company Overview
Company Overview Shares on issue¹: 295,916,682 Substantial shareholders Price per share¹: $0.445 Dr William James Garner³ 15.50% Market capitalisation¹: $131.68m Cash at bank (30 June 2026)²: $12.87m Jason Alan Carroll³ 11.92% Potential additional capital from vested options MWP Partners Limited⁴ 8.
Slide 6: The Filovirus Threat Landscape
The Filovirus Threat Landscape AN URGENT AND GROWING GLOBAL SECURITY CHALLENGE Extremely high fatality rates: Marburg up to 88%, Ebola up to 90%, Sudan up to 47%, Bundibugyo 30–50% Limited BSL-4 pathogens: Bioterror relevance: Current situation: countermeasures: Require maximum Historical Ongoing No
Slide 7: The Preparedness Gap
The Preparedness Gap THERE ARE NO FILOVIRUS THERAPEUTICS CAPABLE OF CROSS-STRAIN PROTECTION Existing Ebola countermeasures No approved therapeutics for are strain-specific (Zaire only) Marburg, Bundibugyo or Sudan virus Outbreaks increasingly involve Stockpile lacks a broad-acting rare or divergent
Slide 8: Why Galidesivir?
Why Galidesivir? A BROAD-ACTING ANTIVIRAL WITH STRONG FILOVIRUS EFFICACY AND FDA-ALIGNED PATHWAY Demonstrated multi-filovirus activity IV and IM formulations with favorable (Marburg, Ebola, Sudan) safety profile Strong in vivo efficacy with delayed Manufacturing route improved with 2– dosing 3X yiel
Slide 9: Broad-spectrum Antiviral Effects Including Filovirus
Broad-spectrum Antiviral Effects Including Filovirus Adjusted EC50 Virus Family Virus Strain/Variant Assay Cell Cell Type EC50 (µM) CLE (µM) Marburg Musoke HCI HeLa 4.4 35% 1.5 Marburg Ci67 HCI HeLa 6.7 35% 2.3 Filoviridae Marburg Angola HCI HeLa 5 35% 1.8 Ebola Zaire (Kikwit) HCI HeLa 11.8 35% 4.1
Slide 10: Marburg NHP Survival
Marburg NHP Survival 94% survival in Marburg (Musoke) NHP Model with treatment initiated up to 48 hours post-infection This level of efficacy, with a clinically meaningful therapeutic window, is rare in filovirus models and directly supports Animal Rule advancement Island Pharmaceuticals Limited 09
Slide 11: Rodent Filovirus Models
Rodent Filovirus Models Supporting evidence across multiple filovirus models MARV – Musoke Aerosolized MARV-Angola Guinea pigs infected with MARV-Musoke or aerosolized MARV- Angola showed strong survival with early and delayed dosing. ⚬ IM, 50mg/kg BID treatment before (BI) or post-infection (PI) TH
Slide 12: FDA Response Significantly De-risks Regulatory Pathway
FDA Response Significantly De-risks Regulatory Pathway FDA confirmed the Clear guidance FDA advised that Island intends to Animal Rule provided on clinical Galidesivir would commence the next pathway is program design – qualify for a Tropical Galidesivir animal appropriate for enables Island to Dise
Slide 13: Animal Rule Is A Proven Path For Bioterror Threat Countermeasures
Animal Rule Is A Proven Path For Bioterror Threat Coutermeasures Since 2012, the FDA’s Animal Rule approval has led to 8 bioterror countermeasures joining the US Strategic National Stockpile (SNS) In 7 out of 8 cases, these medical countermeasures continue to remain under SNS contract and have gener
Slide 14: Ebola NHP Survival
Ebola NHP Survival Robust efficacy in Zaire Kikwit NHP model with delayed dosing Survival of rhesus non-human primates (6 per arm) challenged with Ebola virus (10³) followed 2 or 3 days later by intramuscular administration of 100 mg/kg BID loading dose + 25 mg/kg BID for 10 days. Percentage surviva
Slide 15: Government-Approved Africa Protocol
Government-Approved Africa Protocol Monitored Emergency Use of Unregistered and Investigational Interventions (MEURI) framework Government approvals have been secured to evaluate Galidesivir during the active Bundibugyo Ebola outbreak in Uganda under the WHO MEURI framework, creating a unique opport
Slide 16: Completed Clinical Trial Results
Completed Clinical Trial Results A growing body of clinical evidence supports the continued development of Galidesivir. Delivery Design Highest Study Type Subjects Key Findings Mode (Status) Dose • No SAEs Phase 1 50 (SAD) SAD & MAD 10 mg/kg x • No dose-limiting toxicities 101 (Healthy IM 23 (MAD) (
Slide 17: Dual Development Strategy
Dual Development Strategy Two complementary pathways advancing Galidesivir towards regulatory approval Pathway 1 Pathway 2 Human Ebola Study FDA Animal Rule Program WHO MEURI Framework USAMRIID Marburg challenge study Real-world clinical data Controlled non-human primate efficacy data Bundibugyo Ebo
Slide 18: Multiple commercialisation opportunities
Multiple commercialisation opportunities Galidesivir has the potential to fill multiple gaps in the US government’s biodefence stockpile Non-human PRV Eligible for Animal Rule Strategic National Virus Cell culture data Animal data primate efficacy first indication Potential Stockpile Potential Marbu
Slide 19: Pipeline
Pipeline Advancing innovative therapies for serious global health threats. Animal Pilot Animal Pivotal NDA Compassionate Program IND Enabling Studies Study Phase 1 Phase 2 Phase 3 Submission Use Marburg Ebola Galidesivir Sudan Yellow Fever Zika Dengue Treatment ISLA-101 Dengue Prevention ISLA-6181 A
Slide 20: Near-Term Catalysts
Near-Term Catalysts A number of value catalysts pending in the coming months Milestone Timeframe Establish Fellows Program to provide expert access to strategic subject matter KOLs Complete FDA feedback on Galidesivir protocol clarifying questions Received Government-approved deployment of Galidesiv
Slide 21: Thank You
THANK YOU dfoster@islandpharmaceuticals.com +1 510-393-6523 islandpharmaceuticals.com @IslandPharma Island Pharmaceuticals ASX: ILA